Interleukin-1 Receptor Accessory Protein

A protein that takes part in the formation of active interleukin-1 receptor complex. It binds specifically to INTERLEUKIN-1 and the INTERLEUKIN-1 RECEPTOR TYPE I at the cell surface to form a heterotrimeric complex that brings its cytoplasmic domain into contact with the cytoplasm domain of the TYPE-I INTERLEUKIN-1 RECEPTOR. Activation of intracellular signal transduction pathways from the receptor is believed to be driven by this form of cytoplasmic interaction.

Also Known As:

Networked: 55 relevant articles (1 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sala, Carlo: 4 articles (01/2019 - 01/2010)
2.	Gritti, Laura: 3 articles (01/2019 - 02/2015)
3.	Montani, Caterina: 3 articles (01/2019 - 02/2015)
4.	Billuart, Pierre: 3 articles (12/2017 - 01/2010)
5.	Steidl, Ulrich: 2 articles (01/2022 - 01/2018)
6.	Verma, Amit: 2 articles (01/2022 - 01/2018)
7.	Verpelli, Chiara: 2 articles (01/2019 - 12/2017)
8.	Ramos-Brossier, Mariana: 2 articles (12/2017 - 02/2015)
9.	Chelly, Jamel: 2 articles (02/2015 - 01/2010)
10.	Humeau, Yann: 2 articles (02/2015 - 01/2010)

Related Diseases

1.	Experimental Arthritis 07/01/2005 - "Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist." 10/01/2003 - "Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis."
2.	Neoplasms (Cancer) 11/20/2023 - "Interleukin-1 receptor accessory protein (IL-1RAP): A magic bullet candidate for immunotherapy of human malignancies." 01/01/2022 - "Targeting IL-1RAcP signaling pathway that was recently considered in clinical trials related to malignancies also indicates its potential as therapeutic target for the inflammatory and autoimmune diseases. " 01/01/2018 - "The surface molecule interleukin-1 receptor accessory protein (IL1RAP) is consistently overexpressed across multiple genetic subtypes of acute myeloid leukemia (AML) and other myeloid malignancies, including at the stem cell level, and is emerging as a novel therapeutic target. " 01/01/2021 - "IL-1RAcP has also been implicated in tumor progression in solid tumors and an anti-IL1RAP antibody (nadunolimab, CAN04) is in phase II clinical studies in pancreatic cancer and non-small cell lung cancer (NCT03267316). " 01/01/2021 - "Based on its high affinity, high neutralizing potency, and novel binding epitope simultaneously occupying both IL-1RI and IL-1RAcP residues that bind to IL-1β, IgG26AW may be a new candidate for treatments of inflammation-related diseases or for complementary treatments of cancers in which the role of IL-1β is critical to pathogenesis."
3.	Inflammation (Inflammations) 01/01/2023 - "IL-36 composed of a natural antagonist (IL-36Ra) and three agonists (IL-36α, -β, -γ) that stimulate inflammation by binding to a common receptor consisting of IL-36R and IL-1RAcP. " 01/01/2012 - "IL-1ß plays significant roles in inflammation and immune defense via IL-1RAcP. " 08/01/2003 - "Expression of alternatively spliced interleukin-1 receptor accessory protein mRNAs is differentially regulated during inflammation and apoptosis." 01/01/2021 - "This study was performed to investigate the role of interleukin-1 receptor accessory protein (IL1RAP) in stomach carcinoma in vitro and in vivo, determine whether IL1RAP knockdown could regulate the development of stomach carcinoma, and elucidate the relationship between IL1RAP knockdown and inflammation by tumor microenvironment-related inflammatory factors in stomach carcinoma. " 01/01/2013 - "IL-1RAcPb is an isoform of IL-1RAcP expressed specifically in neurons and promotes their survival during acute inflammation. "
4.	Pancreatic Neoplasms (Pancreatic Cancer) 07/26/2022 - "Correction: Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer." 01/01/2022 - "Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer." 01/01/2021 - "IL-1RAcP has also been implicated in tumor progression in solid tumors and an anti-IL1RAP antibody (nadunolimab, CAN04) is in phase II clinical studies in pancreatic cancer and non-small cell lung cancer (NCT03267316). "
5.	Syncope (Fainting) 08/01/2014 - "The neurophysiologic study (video-electroencephalographic monitoring) revealed the epileptic nature of the stimulus-induced drop attacks, and the comparative genomic hybridization analysis revealed a microdeletion encompassing the interleukin-1 receptor accessory protein like 1 (IL1RAPL1) gene. "

Related Drugs and Biologics

1.	Interleukin-1 Receptors (Interleukin 1 Receptor)
2.	Nonsense Codon (Nonsense Mutation)
3.	Interleukin-1 (Interleukin 1)
4.	Interleukin-33
5.	Cytokines
6.	Messenger RNA (mRNA)
7.	Proteins (Proteins, Gene)
8.	Protein Isoforms (Isoforms)
9.	Neutralizing Antibodies
10.	Aggrecans (Aggrecan)

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Fluid Therapy (Oral Rehydration Therapy)